<DOC>
	<DOCNO>NCT00871741</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity GSK Biologicals ' GSK2202083A vaccine give three-dose vaccination course 3 , 5 11 month age .</brief_summary>
	<brief_title>Feasibility Study GlaxoSmithKline Biologicals ' GSK2202083A Vaccine Healthy Infants 3 , 5 11 Months Age .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female infant , include , 8 16 week time first vaccination . Born gestation period 36 42 week inclusive . Subjects investigator believe parents/ guardian comply requirement protocol . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug since birth . Administration immunoglobulins and/or blood product since birth plan administration study period . Administration vaccine foreseen study protocol within 30 day prior randomisation , plan administration randomisation study Visit 3 , 30 day 30 day study Visit 4 , exception influenza human rotavirus vaccine . The administration vaccine , include conjugated pneumococcal vaccine , allow period one day study Visit 3 31 day study Visit 4 . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product Evidence previous intercurrent diphtheria , tetanus , pertussis , hepatitis B , poliomyelitis , Hib and/or MenC vaccination disease , include HBV vaccination birth . History seizures progressive neurological disease . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . The following condition temporary selflimiting , subject may vaccinate condition resolve exclusion criterion meet : • Current febrile illness axillary temperature &gt; = 38.5 ºC moderate severe illness within 24 hour study vaccine administration</criteria>
	<gender>All</gender>
	<minimum_age>8 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Combined vaccine</keyword>
	<keyword>Primary vaccination</keyword>
</DOC>